Differentiation of human embryonic stem cells into single hormonal insulin positive cells

• US 9,388,386 B2
• Filed: 12/07/2012
• Issued: 07/12/2016
• Est. Priority Date: 12/22/2011
• Status: Active Grant

• Current Assignee: Janssen Biotech, Inc. (Johnson & Johnson)
• Original Assignee: Janssen Biotech, Inc. (Johnson & Johnson)
• Inventors: Rezania, Alireza
• Primary Examiner(s): Singh, Anoop
• Assistant Examiner(s): Montanari, David A
• Application Number:
  US13/708,369
• Publication Number:
  US 20130189777A1
• Time in Patent Office: 1,313 Days
• Field of Search: 435/325, 435/377
• US Class Current: 1/1
• CPC Class Codes: C12N 2500/34 Sugars
• CPC Class Codes: C12N 2500/38 Vitamins
• CPC Class Codes: C12N 2501/117 Keratinocyte growth factors (KGF-1, i.e. FGF-7; KGF-2, i.e. FGF-12)
• CPC Class Codes: C12N 2501/15 Transforming growth factor beta (TGF-β)
• CPC Class Codes: C12N 2501/155 Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
• CPC Class Codes: C12N 2501/16 Activin; Inhibin; Mullerian inhibiting substance
• CPC Class Codes: C12N 2501/19 Growth and differentiation factors [GDF]
• CPC Class Codes: C12N 2501/385 of the family of the retinoic acid recptor, e.g. RAR, RXR; Peroxisome proliferator-activated receptor [PPAR]
• CPC Class Codes: C12N 2501/41 Hedgehog proteins; Cyclopamine (inhibitor)
• CPC Class Codes: C12N 2501/415 Wnt; Frizzeled
• CPC Class Codes: C12N 2501/727 Kinases (EC 2.7.)
• CPC Class Codes: C12N 2506/02 from embryonic cells
• CPC Class Codes: C12N 5/0676 Pancreatic cells

Abstract

The present invention provides methods to promote the differentiation of pluripotent stem cells. In particular, the present invention provides methods to produce a population of cells, wherein greater than 10% of the cells in the population express markers characteristic of single hormonal pancreatic beta cells.

Claims

1. An in vitro method for producing a population of pancreatic cells comprising the steps of:

a) culturing undifferentiated human pluripotent stem cells in a medium supplemented with 5 mM to 20 mM glucose, a TGF-β

ligand, and a WNT activator, to generate a population of definite endoderm (DE) cells;

b) culturing the DE cells in a medium supplemented with 5 mM to 20 mM glucose, and a FGF ligand to generate a population of gut tube cells;

c) culturing the gut tube cells in medium supplemented with 5 mM to 20 mM glucose, a shh inhibitor, a FGF ligand, a PKC activator, a TGF-β

ligand, a retinoid, and a gradient of a BMP inhibitor to generate a population of posterior foregut endoderm cells expressing PDX-1 and SOX2;

d) culturing the posterior foregut cells in medium supplemented with 5 mM to 20 mM glucose, a PKC activator, a shh inhibitor, a retinoid, and a BMP inhibitor to generate a population of pancreatic foregut cells expressing PDX-1 and NKX6.1, and expressing lower level of SOX2 as compared to the posterior foregut cells;

e) culturing the pancreatic foregut cells in medium supplemented with 5 mM to 20 mM glucose, a shh inhibitor, a TGF-β

inhibitor, ascorbic acid and a retinoid to obtain a population of cells, wherein said population comprises;

(i) greater than 30% of pancreatic endoderm cells that are PDX-1+, NKX6.1+, SOX2− and

CDX2−

, and

(ii) greater than 10% of single hormonal insulin positive cells.

2. An in vitro method for differentiating human pluripotent stem cells comprising the steps of:

a) culturing human pluripotent stem cells in a medium supplemented with 5 mM to 20 mM glucose, a TGF-β

ligand, and a WNT activator, to generate a population of definite endoderm (DE) cells;

b) culturing the DE cells in a medium supplemented with 5 mM to 20 mM glucose, and a FGF ligand to generate a population of gut tube cells;

c) culturing the gut tube cells in medium supplemented with 5 mM to 20 mM glucose, a shh inhibitor, a FGF ligand, a PKC activator, a TGF-β

ligand, a retinoid, and a gradient of a BMP inhibitor to generate a population of posterior foregut endoderm cells expressing PDX-1 and SOX2;

d) culturing the posterior foregut cells in medium supplemented with 5 mM to 20 mM glucose, a PKC activator, a shh inhibitor, a retinoid, and a BMP inhibitor to generate a population of pancreatic foregut cells expressing PDX-1 and NKX6.1, and expressing lower level of SOX2 as compared to the posterior foregut cells;

e) culturing the pancreatic foregut cells in medium supplemented with 5 mM to 20 mM glucose, a shh inhibitor, a TGF-β

inhibitor, and a retinoid to obtain a population of pancreatic endoderm cells expressing PDX-1, a higher level of NKX6.1, and a lower level of SOX2 as compared to pancreatic foregut cells; and

f) differentiating the pancreatic endoderm cells into a pancreatic β

-cell population.

4. The method of claim 2, wherein in at least one step the medium is further supplemented with ascorbic acid.

5. The method of claim 4, wherein the pancreatic β

cells are single hormonal insulin-producing cells which are also NKX6.1+ and PDX-1+.

3. An in vitro method for differentiating human pluripotent stem cells comprising the steps of:

a) culturing human pluripotent stem cells in a medium supplemented with 5 mM to 20 mM glucose, a TGF-β

ligand, and a WNT activator, to generate a population of definite endoderm (DE) cells;

b) culturing the DE cells in a medium supplemented with 5 mM to 20 mM glucose, and a FGF ligand to generate a population of gut tube cells;

c) culturing the gut tube cells in medium supplemented with 5 mM to 20 mM glucose, a shh inhibitor, a FGF ligand, a PKC activator, a TGF-β

ligand, a retinoid, and a gradient of a BMP inhibitor to generate a population of posterior foregut endoderm cells expressing PDX-1 and SOX2;

d) culturing the posterior foregut cells in medium supplemented with 5 mM to 20 mM glucose, a PKC activator, a shh inhibitor, a retinoid, and a BMP inhibitor to generate a population of pancreatic foregut cells expressing PDX-1 and NKX6.1, and expressing lower level of SOX2 as compared to the posterior foregut cells;

e) culturing the pancreatic foregut cells in medium supplemented with 5 mM to 20 mM glucose, a shh inhibitor, a TGF-β

inhibitor, and a retinoid to obtain a population of pancreatic endoderm cells expressing PDX-1, a higher level of NKX6.1, and a lower level of SOX2 as compared to pancreatic foregut cells; and

f) differentiating the pancreatic endoderm cells into a pancreatic β

-cell population.

6. The method of claim 3, wherein the pancreatic β

-cell population is PDX-1+, NKX6.1+, SOX2-, and CDX2-.